Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
good move...already pulling back up to 18.50.
thanks for the other message. I'll dip in a toe just on your reco.
Finally picked some ICEL up here in mid 17's....
A better version, with some questions addressed....
Little Known Cynapsus Underway To Solve Crucial Problem For Parkinson's Sufferers
Sep 30 2013, 21:48 | about: CYNAF.PK, includes: ACRX, ARWR, ONXX, SLXP
Little Known Cynapsus Underway To Solve Crucial Problem For Parkinson's Sufferers
Unearthing and investing in undervalued stocks is risky, challenging, and rewarding. Canadian micro-cap Cynapsus (CYNAF.PK) appears decidedly undervalued.
Parkinson's Disease (PD is a progressive degenerative disease of the central nervous system that affects more than 5 million individuals in the developed world, with prevalence increasing as longer life spans bulk elderly populations. Great demand exists for improvements in Parkinson's treatment. Cynapsus is a clinical stage Canadian micro-cap company, presently conducting Phase 1b human trials of a sublingual form of the injectable Parkinson's disease drug apomorphine, with results due 4Q 2013. Apomorphine is a proven, safe, effective rescue medication marketed as Apokyn, which counters debilitating "freeze-up" or "off" episodes common in Parkinson's patients. "Off" episodes can be one of the most debilitating daily symptoms associated with Parkinson's.
Sales of Apokyn have been limited, in no small part due to discomfort and side-effects associated with daily self-injection or injection by caregivers. The advantages of a sublingual delivery system over an injectable one for semi-immobilized patients is obvious.
Cynapsus is led by a well-respected team that brings with them decades of experience in development stage biotechnology companies, specifically in the neurology space.Cynapsus present Phase 1b titration trials for the product, APL-130277, utilizes healthy volunteers, with no Parkinson's patients needed to show proof of concept. APL-130277, patented as of April 2013, should be patent protected to 2031.
In this Phase 1 trial, Cynapsus must demonstrate effective blood levels of apomorphine without injection-site reactions. I believe these initial trial results will be positive, and an initial mover of the share price northward for Cynapsus, with now the time to enter the long side of the trade.
In July 2010, Cynapsus released results of a survey done on 50 neurologists who jointly treat about 12,000 PD patients. The results of the survey affirmed the APL-130277 product concept. In November 2010, another survey was conducted on Health Maintenance Organizations and insurers; favorable results indicated APL-130277 may be accepted by payers similarly to apomorphine injection. In December 2010, Cynapsus completed pre-clinical studies on rabbits which demonstrated that APL-130277 thin film strip was able to deliver apomorphine into the blood stream. In December of 2011, Cynapsus surveyed 500 neurologists on who treat about 62,000 PD patients, with favorable results simllar to the earlier physician study. In January 2012, Cynapsus announced positive data from the first human proof-of-concept study of APL- 130277. The study showed a PK profile that compared to injected apomorphine.
Jason Napodano CFA, biotech analyst for Zack's Investment Research and Editor at Propthink, is renowned for his acumen in identifying winners in biotech. Napodano initiated coverage for Cynapsus on June 4, 2013 for Zack's, and strongly recommended Cynapsus on August 1 and August 23 in the Life Science's Report (see links below). On August 1st, Napodano had this to say about CYNAF : "If this were a U.S. stock, it would be four or five times the price it is now, but because it's in Canada, no one knows about it. Cynapsus reminds me a lot of Cipher when it was trading at $0.64 and no one was looking at it. All of a sudden, people started to take notice. That's where Cynapsus is right now." In his article of June 4th, entitled "Cynapsus, an Undiscovered Gem", Napodano, who as a prognosticator is wise to under-promise and over-deliver, describes current fair value of CYNAF shares as $1.25. His bullet points included:
"-The PD market is large, growing rapidly, and highly under-served.
- The company is not trying to reinvent the wheel with APL-130277. The product is an astutely designed re-formulation of an existing approved and known-to- be effective product, Apokyn.
- The company held a pre-IND meeting with the agency confirming the path to approval is bioequivalence to the reference product, subcutaneous apomorphine via the 505(b)(2) pathway.
- The company seeks the same indication for use as Apokyn, reducing risk that the FDA comes back and asks for new efficacy studies. We see low clinical development risk here.
- Based on the patient filings and existing pharmacokinetic data from CTH-102, the formulation and intellectual property protection seem solid."
Napodano also notes "…the potential for an outright acquisition of Cynapsus by a larger pharma player. The Pfizer / Nextwave deal for $700 million, for example, pegs the Cynapsus valuation at nearly 40x the current valuation."
Hugh Cleland manages Blumont Capital, which specializes in ground floor market opportunities, much like a venture capitalist. He invests in micro-cap and international stocks overlooked by mainstream institutional investors. Cleland's goal is to support worthwhile companies as well as reap outsized gains when worthy companies "hit the radar". Cleland holds CYNAF as a core holding, and had this to say about Cynapsus on June 27th: "It has made huge strides… including closing a financing of $7.3M, which greatly reduces financing risk….it was very encouraging to see a specialty pharma company (Dexcel Pharma Ltd. [private]) as the lead investor, taking a 19.6% stake in Cynapsus."
With a float of under 40 million shares and a market cap of around 17 million, CYNAF has plenty of room on the upside.
Nathan Cali, Senior Research Analyst, Biotechnology and Specialty Pharmaceuticals, at Noble Financial Capital Markets initiated coverage of CYNAF on July 13, 2013, with a price target of 1.75. He believes "APL-130277 could expand market, global potential exceeds two billion, high-value near-term clinical data expected Q4 2013... significant partnerships/acquisition 2014/2015"
In August 2012, the Michael J. Fox Foundation (MJFF), a prominent force in PD research, awarded Cynapsus Therapeutics with a grant in the amount of $947,925 to help fund further research in the development of APL- 130277. This Fox Foundation grant, will be funding Cynapsus Phase II trials, likely to begin in early 2014. The Fox Foundation clearly stands behind APL-130277 .
In parallel, AcelRx Pharmaceuticals (ACRX), has developed an improved delivery syste, similar to sublingual, for an already approved pain medication. As proof of bioequivalency and efficacy are being achieved in stages, shares of ACRX have risen from the $3 range in early 2013 to the $10 range, and are considered by many to hold continued upside potential. Several medications delivered in sublingual form now have billion dollar sales volume, and the list of sublingual drugs continues to grow.
Ori Hershkovitz, managing editor of Tel-Aviv based Sphera Global Healthcare Fund, described Cynapsus on May 30, 2013 as "very small company that is very early in the game with a very good and relatively derisked idea…Sometimes investors should invest early, and every now and then we come across a very early-stage story " He notes of CYNAF, "If apomorphine could be reformulated as a noninjectable product, it could be a billion-dollar therapy" In that article, Hershkovitz recommended Arrowhead Research (ARWR) at $2.35 (Arrowhead as of September has crossed the $6 mark), Onyx Pharmaceuticals (ONXX), which has risen from $90 to over $124, and Salix Pharmaceuticals (SLXP) which has traded up twenty percent. Hershkovitz displays evident talent for picking winners.
Microcap investing is by nature risky, and Microcap biotech investing even more so. Unexpected problems or delays can arise during clinical trials which can be difficult or devastating to a stock such as CYANF, which is dependent upon one product. An adverse event during a trial can erase capital faster than an investor can react.
Cynapsus has initiated trade on the OTCQX as of July 18, 2013, and is a fully reporting company. Currently, however, it is thinly traded, and when volume appears in thinly traded OTC stocks, sudden and unexpected movements in share price can occur, up and down.
While Cynapsus appears well-financed and is garnering institutional support at present, dilution may occur downstream as trials progress through the necessary stages towards FDA approval. Cynapsus' drug is being developed through the FDA's 505(b)(2) regulatory pathway, under which older drugs are reformulated, as opposed to the new molecular entity (NME) or new chemical entity pathways proceeding through to new drug applications (NDAs) While the latter receive greater investor attention, the less glamorous pathway allows for an affordable entry into CYANF .
It is mission critical the Phase 1b trial prove the sublingual formulation can maintain a level of apomorphine equivalent to the injection of apomorphine over a set period of time, with fewer side-effects than injection. Development of alternative formulations of apomorphine have thus far met with little success; stomach enzymes interfere with uptake of apomorphine tablets and necessitate excessively high dosage to achieve efficacy, and intranasal administration has produced undesirable topical side effects such as buring of the nasal mucosa. One must trust as an investor that Cynapsus has the know-how to transcend these challenges, perhaps placing dissolvable emollients or waxes on the strip, (emollients which would not disperse well in a nasal spray). An oral dissolvable delivery system will wash down the mucosa with saliva and imbibed fluids, preventing burning of the tissue.
To the noteworthy analysts quoted above, Cynapsus appear to be heading in the right direction, and represents a worthy investment. Cynapsus has already completed two pharmacokinetic, bioavailability dose escalation studies. Based upon the company's film strip delivery compared to Apokyn, APL-130277 achieved comparable safety and has extrapolated equivalent dose strength formulations to potentially achieve efficacy and safety under an FDA approved 505b2 clinical development pathway. Importantly, the side effect profile was similar to that of Apokyn except for site irritation in Cynapsus sublingual application. No site irritation was evident in either Cynapsus study while taking the APL-130277 film strip, and that is "the right answer".
Good luck to all in investing.
Sources: www.cynapsus.ca/index.php
http://www.cynapsus.ca/melonhead/media/1373921868.pdf
https://docs.google.com/file/d/0B10OUaQZjkpOVDkwWXpXMUxYcGM/edit?pli=1
http://finance.yahoo.com/news/initiating-coverage-cynapsus-therapeutics-undiscovered-120000975.html
http://www.thelifesciencesreport.com/pub/na/small-cap-biotechs-with-blockbuster-potential-hugh-cleland
http://www.thelifesciencesreport.com/pub/na/off-to-the-races-with-seven-extraordinary-biotech-and-medtech-companies-jason-napodano
http://seekingalpha.com/instablog/1256651-life-sciences-report/1907941-new-perspectives-and-seven-biotechs-for-a-diversified-portfolio-ori-hershkovitz
http://seekingalpha.com/author/life-sciences-report/instablog/symbol/cynaf.pk
http://www.thelifesciencesreport.com/pub/co/4825
Disclosure: I am long CYNAF.PK. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article
Do me a favor please, save that and erase the post, i dont have PM, wanted to share with you, but didnt necessarily want to broadcast...
Here's a sneak preview the the SA article i'm publishing shortly...thought you might appreciate
Little Known Cynapsus Underway To Solve Crucial Problem For Parkinson's Sufferers
Unearthing undervalued stocks can be both challenging and rewarding. Canadian micro-cap Cynapsus (ticker symbol CYNAF) appears decidedly undervalued.
Parkinson's disease is a progressive degenerative disease of the central nervous system that affects more than 5 million individuals in the developed world, with prevalence increasing as longer life spans bulk elderly populations. Great demand exists for improvements in Parkinson's treatment. Cynapsus is a clinical stage Canadian micro-cap company, developing a sublingual form of the injectable Parkinson's disease drug apomorphine. Apomorphine is a proven effective rescue medication marketed as Apokyn, which counters debilitating "freeze-up" or "off" episodes common in Parkinson's patients. "Off" episodes can be one of the most debilitating daily symptoms associated with Parkinson's.
As sales of Apokyn have been limited due to the need for daily self-injection or injection by caregivers, the advantages of a sublingual delivery system over an injectable one for semi-immobilized patients is obvious.
Cynapsus is led by a well-respected team that brings with them decades of experience in development stage biotechnology companies, specifically in the neurology space.
Cynapsus phase 1 titration trials for the product, APL-130277, are slated to render results in 4Q 2013. This Phase 1 study utilizes healthy volunteers, with no Parkinson's patients needed to show proof of concept. APL-130277, patented as of April 2013, is patent protected to 2031.
In this Phase 1 trial, Cynapsus must demonstrate effective blood levels of apomorphine without injection-site reactions. I believe these initial trial results will be positive, and an initial mover of the share price for Cynapsus, with now the time to enter the long side of the trade.
In July 2010, Cynapsus released results of a survey done on 50 neurologists who jointly treat about 12,000 Parkinson's patients. The results of the survey affirmed and validated the APL-130277 product concept. In November 2010, another survey was conducted, this time on Health Maintenance Organizations and insurers. The results of the survey were favorable and indicated that APL-130277 may be accepted by payers near the level at which apomorphine injection is currently reimbursed. In December 2010, Cynapsus announced the completion of pre-clinical studies on rabbits and the results showed that APL-130277 thin film strip was able to deliver apomorphine into the blood stream. In December of 2011, Cynapsus announced results from the Global 500 Neurologists Survey. In this survey 500 neurologists were surveyed on their treatment of patients with Parkinson's disease. As a group the 500 neurologists treat about 62,000 Parkinson's patients. The results were favorable as was the smaller survey conducted a year before. In January 2012, Cynapsus announced positive data from the first human proof-of-concept study of APL- 130277. The study showed a PK profile that compared to injected apomorphine.
Jason Napodano CFA, biotech analyst for Zack's Investment research and Editor at Propthink, is renowned for his acumen in identifying winners in biotech. Napodano initiated coverage for Cynapsus on June 4, 2013 for Zack's, and strongly recommended Cynapsus on August 1 and August 23 in the Life Science's Report. On August 1st, Napodano had this to say about CYNAF : "If this were a U.S. stock, it would be four or five times the price it is now, but because it's in Canada, no one knows about it. Cynapsus reminds me a lot of Cipher when it was trading at $0.64 and no one was looking at it. All of a sudden, people started to take notice. That's where Cynapsus is right now." In his article of June 4th, entitled "Cynapsus, an Undiscovered Gem", Napodano, who as a prognosticator is wise to under-promise and over-deliver, describes current fair value of CYNAF shares as $1.25. His bullet points included:
"-The Parkinson's disease market is large, growing rapidly, and highly under-served.
- The company is not trying to reinvent the wheel with APL-130277. The product is an astutely designed re-formulation of an existing approved and known-to- be effective product, Apokyn.
- The company held a pre-IND meeting with the agency confirming the path to approval is bioequivalence to the reference product, subcutaneous apomorphine via the 505(b)(2) pathway.
- The company seeks the same indication for use as Apokyn, reducing risk that the FDA comes back and asks for new efficacy studies. We see low clinical development risk here.
- Based on the patient filings and existing pharmacokinetic data from CTH-102, the formulation and intellectual property protection seem solid."
Napodano also notes "…the potential for an outright acquisition of Cynapsus by a larger pharma player. The Pfizer / Nextwave deal for $700 million, for example, pegs the Cynapsus valuation at nearly 40x the current valuation."
Hugh Cleland manages Blumont Capital, which specializes in ground floor market opportunities, much like a venture capitalist. He invests in stocks too small for institutional investment, reaping outsized gains when worthy companies "hit the radar". Mr. Cleland holds CYNAF as a core holding, and had this to say about Cynapsus on June 27th: "It has made huge strides… including closing a financing of $7.3M, which greatly reduces financing risk….it was very encouraging to see a specialty pharma company (Dexcel Pharma Ltd. [private]) as the lead investor, taking a 19.6% stake in Cynapsus." With a float of under 40 million shares and a market cap of around 17 million, CYNAF has plenty of upside.
Nathan Cali, Senior Research Analyst, Biotechnology and Specialty Pharmaceuticals, at Noble Financial Capital Markets initiated coverage of CYNAF on July 13, 2013, with a price target of 1.75. He believes "APL-130277 could expand market, global potential exceeds two billion, high-value near-term clinical data expected Q4 2013... significant partnerships/acquisition 2014/2015"
In August 2012, the Michael J. Fox Foundation (MJFF) awarded Cynapsus Therapeutics with a grant in the amount of $947,925 to help fund further research in the development of APL- 130277. The Fox Foundation, prominent in Parkinson's research, will be funding Cynapsus Phase II trials, likely to begin in early 2014, and clearly stand behind APL-130277 .
In parallel, AcelRx Pharmaceuticals (ACRX), has developed an improved delivery system for an already approved pain medication. As proof of bioequivalency and efficacy are being achieved in stages, shares of ACRX have risen from the three dollar range in early 2013 to the ten dollar range, and are considered by many to hold continued upside potential. Medications delivered in sublingual form are growing in both in number and sales volume.
Ori Hershkovitz, managing editor of Tel-Aviv based Sphera Global Healthcare Fund, described Cynapsus on May 30, 2013 as "very small company that is very early in the game with a very good and relatively derisked idea…Sometimes investors should invest early, and every now and then we come across a very early-stage story " He notes of CYNAF, "If apomorphine could be reformulated as a noninjectable product, it could be a billion-dollar therapy" In that article, Hershkovitz recommended Arrowhead Research, which closed for trading that day at $2.35. ARWR as of September has crossed the six dollar mark, Onyx Pharmaceuticals, which has risen from $90 to over $124, and Salix Pharmaceuticals which has traded up twenty percent. Hershkovitz displays evident talent for picking winners.
CYNAF has initiated trade on the OTCQX as of July 18, 2013, and is a fully reporting company, not a "pink sheet". Currently it is thinly traded, however, and when volume and volatility appears in thinly traded OTC stocks, unexpected movements in share price can occur. While CYNAF appears well-financed and is garnering institutional support at present, dilution may occur downstream as trials progress through the necessary stages towards FDA approval. Cynapsus' present low valuation could be due in part to a lack of respect for drugs being developed through the FDA's 505(b)(2) regulatory pathway, under which older drugs are reformulated, as opposed to the new molecular entity (NME) or new chemical entity pathways proceeding through to new drug applications (NDAs), which receive greater investor attention. This factor, however, is helping to keep Cynapsus "under the radar" at present and allow for affordable entry.
Cynapsus is thus far, a one-trick pony. Trial results from the present Phase one trial must prove the sublingual formulation can maintain a level of apomorphine equivalent to the injection of apomorphine over a certain period of time, with fewer side-effects than injection. Development of alternative formulations of apomorphine have thus far met with little success; stomach enzymes interfere with uptake of apomorphine tablets and necessitate excessively high dosage to achieve efficacy, and intranasal administration has produced undesirable topical side effects. One must trust as an investor that Cynapsus has the know-how to transcend these challenges. To the professional investment class examining their progress carefully, they appear to be making progress, and represent a worthy investment. The company has completed two pharmacokinetic, bioavailability dose escalation studies. Based upon the company's film strip delivery compared to the reference listed drug, Apokyn, APL-130277 achieved comparable safety and has extrapolated equivalent dose strength formulations to potentially achieve efficacy and safety under an FDA approved 505b2 clinical development pathway. Importantly, the side effect profile was similar to that of Apokyn except for site irritation, no site irritation was shown in either study while taking APL-130277 film strip.
Good luck to all in investing.
www.cynapsus.ca/index.php
Nice pullback to 20 today...picked up more. seems like the bounce back to trend has already started.
Congrats on getting in this early...real good strength here, up on a down day for biotechs.
I've got another one I like as well, on hold before I can mention it for a few days, but believe you'll be intrigued.
No question that ICEL is starting to get some attention. CLDX, TSRX, CTIX and NNVC were my other picks for the year, so I've been fortunate.
A couple of these will carry over into next year, but I've got some leads and will let you know about the next few that I like.
You crushed it with this one Noretreat....whats next?
Welcome. Cellular Dynamics are leaders in many stem cell technologies. THey've been public since late July. You can check some of their more recent programs in the intro, where there is a list of press releases. And, of course, there is much more info here.
http://www.cellulardynamics.com/
I'd just got a tip about ICEL today from a buddy at work. Thought I'd checked in this Board...
What's the scoop, pipelines on ICEL? Definitely this stock is perking my interest....
Well, so much for weakness...
I like this stock and it is almost a doubler, but the answer to the value question eludes me. Therefore, my position is small relative to stocks like CTIX or some of my more conservative holdings.
ICEL looks promising here, will place on watch to buy on any weakness and inception of options trading...low float is a plus.
Another IPO to look out for is Sumagen...private company with some very good trial news this weekend. They could be subsumed before ever going public based on what I've read, but one never knows.
After doubling my speculative IRA account last fall with shares and options on a play that spiked from 2 's to 5's, I traded the other stock we often comment upon like a ninny this year. Importance of monitoring indicators and remaining dispassionate can never be minimized.
I have seen you consistently remain "clear".
You have earned the respect.
Thanks, but you are WAY too kind. I have smart friends who sometimes share their analysis with me.
I always enjoy your posts on the other boards.
On Day One ICEL dropped from the IPO price of 12 to 9.50, but the initial shareholders that wanted to sell were relatively few and there are apparently quite a few others that continue to want in. Establishing a value based on financials is difficult (at least for me) at this point, but the market is saying the company is worth quite a bit more than the IPO price. Awareness of the stock is still near zero, so this rally may have long legs as awareness builds. I may still accumulate a bit...
The recent quarterly report showed pretty good growth rates vs. both yr ago and previous qtr.
Got my vote as the smartest trader I can find on IHUB.
Please keep posting.
been watching this one since before it started trading, just noticed a board was made..
I thought it was gonna trade down first, but its been heading up fast.
Up 74% since the first day of trading. From $9.50 to $16.50 This one is going up, folks.
2nd Annual CDI User Group Meeting last week...quite a lineup
Confirmed Speakers
Keynote Speaker: Leroy Hood, PhD, Institute for Systems Biology
Anne Bang, PhD, Sanford Burnham
M. Eileen Dolan, PhD, University of Chicago
James Hickman, PhD, University of Central Florida
Roberto Iacone, PhD, Hoffmann-La Roche
Salman Khetani, PhD, Colorado State University
Edward LeCluyse, PhD, The Hamner Institutes
Jonathan Lee, PhD, Eli Lilly
Jyoti Malhotra, PhD, Proteostasis Therapeutics
Dinah Misner, PhD, Genentech
William Murphy, PhD, University of Wisconsin – Madison
Matthew Peters, PhD, AstraZeneca
Sharon Presnell, PhD, Organovo
Sonia Santos, PhD, Pfizer/Neusentis
Hong Shi, MD, Bristol-Myers Squibb
Cellular Dynamics and Coriell Institute for Medical Research Awarded Multi-Million Dollar Grants from California Institute for Regenerative Medicine to Manufacture and Bank Stem Cell Lines
http://www.cellulardynamics.com/news/pr/2013_03_21.html
I agree. The recent IPO left them with lots of cash, and gave us a chance to get in early. Still hard to value the company right now but trends are moving in the right direction.
1Q 2013 sales were $1.75M...that's a 65% seq increase from 1Q...pretty good. Gross margins grew to 66% vs. 64% in 1Q.
also cash position looks healthy to absorb the losses.
09:23 AM EDT, 08/29 Cellular Dynamics International (ICEL:$12.76,00$0.05,000.39%) reported a Q2 loss of $2.92 per share, compared with the prior-year period's $3.58 per share. Analysts polled by Capital IQ were expecting a loss of $0.40 per share, but it is unclear if this is comparable.
Revenues were $2.8 million, up 123% from $1.3 million in the same quarter last year. The Street view is for revenues of $2.88 million.
Shares closed at $12.71 with a 52-week range of $9.50 - $14.47.
Cellular Dynamics introduces iCell® Cardiomyocytes, human induced pluripotent stem (iPS) cell-derived cardiomyocytes. These human cardiac cells are specifically designed to aid drug discovery and improve the predictability of drug efficacy and toxicity screens, weeding out ineffective and potentially toxic compounds early in the pharmaceutical pipeline process before significant time and resources have been invested.
http://www.cellulardynamics.com/products/cardiomyocytes.html
Hard to say with a listing this new. But the stock is showing strength. It is up almost 50% from the post-IPO low.
I'm a buyer.
Welcome to the IHub Cellular Dynamics Board!
Cellular Dynamics is developing and deploying a number of cell types derived from induced pluripotent stem (iPS) cells in additional to providing custom services to aid in life science research and drug discovery.
iCell Cardiomyocytes
iCell Endothelial Cells
iCell Hepatocytes
iCell Neurons
iCell Prototypes
MyCell Products
http://www.cellulardynamics.com/index.html
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
87
|
Created
|
08/08/13
|
Type
|
Free
|
Moderators |
Jul 30, 2013 | Cellular Dynamics International Announces Closing of Initial Public Offering |
Jul 24, 2013 | Cellular Dynamics International Announces Pricing of Initial Public Offering |
Jul 10, 2013 | Cellular Dynamics International Announces Launch of Initial Public Offering |
Jun 5, 2013 | |
Jun 4, 2013 | Cellular Dynamics International Files Registration Statement for Proposed Initial Public Offering |
Apr 1, 2013 | |
Mar 21, 2013 | |
Mar 8, 2013 | |
Jan 17, 2013 | Cellular Dynamics Announces the Production of Human iPSC Lines Under cGMP Conditions |
Jan 3, 2013 | |
Dec 18, 2012 | GE Healthcare and Cellular Dynamics International Agree to Sublicense for Cellular Assay Patents |
Dec 12, 2012 | |
Oct 24, 2012 | |
Aug 14, 2012 | |
Jun 12, 2012 | |
Jun 7, 2012 | |
Mar 28, 2012 | |
Mar 8, 2012 | |
Jan 4, 2012 | Cellular Dynamics International to Present at 30th Annual JPMorgan Healthcare Conference |
Dec 13, 2011 | Cellular Dynamics Announces Commercial Launch of iCell Neurons for Neuroscience Drug Discovery |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |